Stock Events

Stock Events

Aura Biosciences 

$6.62
0
+$0+0% Wednesday 04:00

Statistics

Day High
6.63
Day Low
6.62
52W High
-
52W Low
-
Volume
14
Avg. Volume
-
Mkt Cap
420.39M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Next
-0.46
-0.44
-0.42
-0.4
Expected EPS
-0.403333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
2023
2024
0Revenue
-173.84MNet Income

Analyst Ratings

17.5Average Price Target
The highest estimate is 22.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AURA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics AG is involved in gene editing and therapy, competing in the broader biotech space for cancer treatments.
Gilead Sciences
GILD
Mkt Cap172.51B
Gilead Sciences, Inc. has a strong presence in oncology and infectious diseases, making it a competitor in the cancer treatment market.
Incyte
INCY
Mkt Cap19.12B
Incyte Corporation has a portfolio of products targeting cancer, including therapies that could compete with Aura Biosciences' treatments.
Moderna
MRNA
Mkt Cap20.21B
Moderna, Inc., known for mRNA technology, is expanding into cancer vaccines, potentially competing with Aura Biosciences' approach to cancer treatment.
Novartis
NVS
Mkt Cap297.35B
Novartis AG, a large pharmaceutical company, has a diverse oncology portfolio that includes treatments which could compete with Aura Biosciences.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. has a broad range of cancer therapies and is heavily invested in research and development, making it a competitor.

About

Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Show more...
CEO
ISIN
US05153U1079

Listings

XNAS
US
AURA
BOATS
BOATS
AURA.BOATS

0 Comments

Share your thoughts

FAQ

What is Aura Biosciences stock price today?▼
The current price of AURA.BOATS is $6.62 USD — it has increased by +0% in the past 24 hours. Watch Aura Biosciences stock price performance more closely on the chart.
What is Aura Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aura Biosciences stocks are traded under the ticker AURA.BOATS.
What is Aura Biosciences market cap?▼
Today Aura Biosciences has the market capitalization of 420.39M
When is the next Aura Biosciences earnings date?▼
Aura Biosciences is going to release the next earnings report on May 07, 2026.
What were Aura Biosciences earnings last quarter?▼
AURA.BOATS earnings for the last quarter are -0.4 USD per share, whereas the estimation was -0.46 USD resulting in a +13.79% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Aura Biosciences revenue for the last year?▼
Aura Biosciences revenue for the last year amounts to 0 USD.
What is Aura Biosciences net income for the last year?▼
AURA.BOATS net income for the last year is -173.84M USD.
In which sector is Aura Biosciences located?▼
Aura Biosciences operates in the Other sector.
When did Aura Biosciences complete a stock split?▼
Aura Biosciences has not had any recent stock splits.